Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects - PubMed (original) (raw)

Randomized Controlled Trial

Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects

T Jauhiainen et al. Eur J Clin Nutr. 2010 Apr.

Abstract

Background: The milk casein-derived biologically active tripeptides, isoleucyl-prolyl-proline (Ile-Pro-Pro) and valyl-prolyl-proline (Val-Pro-Pro), have documented antihypertensive effect probably related to reduced angiotensin formation. It has been suggested that these tripeptides may reduce arterial stiffness and improve endothelial function. Our aim was to evaluate whether the milk-based drink containing Ile-Pro-Pro and Val-Pro-Pro influence arterial stiffness, measured as augmentation index (AIx), and endothelial function in man.

Methods: In a double-blind parallel group intervention study, 89 hypertensive subjects received daily peptide milk containing a low dose of tripeptides (5 mg/day) for 12 weeks and a high dose (50 mg/day) for the following 12 weeks, or a placebo milk drink to titrate the dose-response effect. Arterial stiffness was assessed by pulse wave analysis at the beginning and end of each intervention period. Endothelial function was tested by examining pulse wave reflection response to sublingual nitroglycerin and salbutamol inhalation. Blood pressure was measured by using office and 24-h ambulatory blood pressure measurement.

Results: At the end of the second intervention period, AIx decreased significantly in the peptide group compared with the placebo group (peptide group -1.53% (95% confidence interval (CI) -2.95 to -0.12), placebo group 1.20% (95% CI 0.09-2.32), P=0.013). No change in endothelial function index was observed (peptide group 0.02 (95% CI -0.06 to 0.08), placebo group 0.04 (95% CI -0.04 to 0.12), P=0.85). There were no statistically significant differences between the effects of the peptide and placebo treatment on office and 24-h ambulatory blood pressure.

Conclusions: Long-term treatment with Lactobacillus helveticus-fermented milk containing bioactive peptides reduces arterial stiffness expressed as AIx in hypertensive subjects.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Augmentation index (AIx) change to 24 weeks. Bars represent 95% confidence intervals.

Figure 2

Figure 2

The changes of augmentation index (AIx) to 24 weeks on subjects with (IDF+) or without metabolic syndrome (IDF−) according to the International Diabetes Federation (IDF) definition for metabolic syndrome.

Similar articles

Cited by

References

    1. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertens. 2005;45:1194–1199. - PubMed
    1. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertens. 2002;39:10–15. - PubMed
    1. Chen C, Nevo E, Fetics B, Pak P, Yin F, Maughan W, et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997;95:1827–1836. - PubMed
    1. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertens. 2005;45:980–985. - PubMed
    1. Engberink MF, Schouten EG, Kok FJ, van Mierlo LA, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hypertension. 2008;51:399–405. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources